Lechebnye effekty gormonal'nykh kontratseptivov (obzor literatury)
- Authors: Podzolkova NM1, Korennaya VV1
-
Affiliations:
- Issue: Vol 14, No 2 (2012)
- Pages: 57-61
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/33313
- ID: 33313
Cite item
Full Text
Abstract
References
- Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004; (Suppl. 4), 190: 5-22.
- Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362: 185-91.
- Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000; 355: 922-4.
- Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-caontaining low-dose oral contraceptive. Contraception 2002; 66: 393-9.
- Winkler UH, Ferguson H, Mulders J. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 µg ethinylestradiol. Contraception 2004; 69: 469-76.
- Davis A, Godwin A, Lippman J et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96: 913-20.
- Reid RL. (2004) Premenstrual syndrome. http://www.endotext.org/female/female10/femaleframe10.htm
- Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-9.
- Borenstein J, Yu H-T, Wade S et al. Effect on an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health related quality of life. J Reprod Med 2002; 48: 79-85.
- Prentice A. Endometriosis. BMJ 2001; 323: 93-5.
- Vercellini P, Fedele L, Pietropaolo G et al. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003; 9: 387-96.
- Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis (Cochrane Review). In the Cochrane Library, Oxford, Issue 1. Oxford: Update Software, 2003.
- Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). In the Cochrane Library, Oxford, Issue 1. Oxford: Update Software, 2003.
- Vercellini P, Frontino G, De Giorgi O et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Fertil Steri 2003; 80: 560-3.
- Meresman GF, Augé L, Barañao RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril 2002; 77: 1141-7.
- Cosson M, Querleu D, Donnez J et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77: 684-92.
- Vercellini P, De Giorgi O, Mosconi P et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52-61.
- Fedele L, Bianchi S, Zanconato G et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485-8.
- The Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis. Guideline 2000; 24.
- Thiboutot D, Archer DF, Lemay A et al. A randomized, controlled trial of a low-dose contraceptive containing 20 mg of ethinyl estradiol and 100 mg of levonorgestrel for acne treatment. Fertil Steril 2001; 76: 461-8.
- Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004, CD004425.
- Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726-35.
- Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003, CD001125.
- Petitti DB, Piaggio G, Mehta S et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 2000; 95: 736-44.
- Kuohung W, Borga TTA, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based approach. Contraception 2000; 61: 77-8.
- Reed SD, Scholes D, LaCroix AZ et al. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 2003; 68: 177-82.
- Nappi C, Di Spiezio Sardo A, Acunzo G et al. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003; 67: 355-59.
- Endrikat J, Mih E, Dusterberg K et al. A 3-year double-blind randomized controlled study on the influence of two oral contraceptives containing either 20 µg or 30 µg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 2004; 69: 179-87.
- Castelo-Branco C, Vicente JJ, Pons F et al. Bone mineral density in young, hypothalamic oligomenorrheic women treated with oral contraceptives. J Reprod Med 2001; 46: 875-79.
- Gordon CM, Grace E, Emans SJ et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa. J Clin Endocrinol Metab 2002; 87: 4935-41.
- Munoz MT, Morande G, Garcia-Centenera JA et al. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 2002; 146: 45-50.
- Grinspoon S, Thomas L, Miller K et al. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002; 87: 2883-91.
- Reproductive Health and Research World Health Organization. Improving access to quality care in family planning. Medical eligibilty criteria for contraceptive use. World Health Organization. Geneva, 2004.
- Burkman RT, Collins JA, Schulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001; 185: 4-12.
- Wise LA, Palmer JR, Harlow BL et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159: 113-23.
- Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women aged 25-40 years. Acta Obstet Gynecol Scand 2000; 79: 202-7.
- Westhoff C, Britton JA, Gammon MD et al. Oral contraceptives and benign ovarian tumours. Am J Epidemiol 2000; 152: 242-6.
- The ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16: 1527-35.